bioAffinity Technologies to be Acquired
Ticker: BIAFW · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1712762
Sentiment: neutral
Topics: acquisition, merger, definitive-agreement
TL;DR
BIOAFFINITY TECHNOLOGIES GETTING BOUGHT OUT - DEAL EXPECTED Q4 2025
AI Summary
bioAffinity Technologies, Inc. announced on September 5, 2025, that it has entered into a definitive agreement to be acquired by an unaffiliated third party. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions. Further details regarding the acquisition were not disclosed in this filing.
Why It Matters
This acquisition signals a potential exit for shareholders of bioAffinity Technologies, Inc., with the transaction anticipated to close by the end of 2025.
Risk Assessment
Risk Level: medium — The risk level is medium due to the pending acquisition, which introduces uncertainty regarding the final terms and completion of the deal.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- September 5, 2025 (date) — Date of earliest event reported
- BIAF (company) — Trading Symbol for Common Stock
- BIAFW (company) — Trading Symbol for Warrants
- The Nasdaq Stock Market LLC (company) — Exchange where securities are registered
FAQ
What is the nature of the event reported in this 8-K filing?
bioAffinity Technologies, Inc. reported that it has entered into a definitive agreement to be acquired by an unaffiliated third party.
When is the expected closing date for the acquisition?
The transaction is expected to close in the fourth quarter of 2025.
What are the trading symbols for bioAffinity Technologies, Inc.'s securities?
The trading symbols are BIAF for Common Stock and BIAFW for Warrants to purchase Common Stock.
On which exchange are bioAffinity Technologies, Inc.'s securities traded?
The Common Stock and Warrants are traded on The Nasdaq Stock Market LLC.
Are there any specific financial details or dollar amounts mentioned regarding the acquisition in this filing?
No specific financial details or dollar amounts regarding the acquisition are disclosed in this particular 8-K filing.
Filing Stats: 625 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-05 17:30:22
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 626KB
- ex99-1_002.jpg (GRAPHIC) — 1151KB
- ex99-1_003.jpg (GRAPHIC) — 1109KB
- ex99-1_004.jpg (GRAPHIC) — 1066KB
- ex99-1_005.jpg (GRAPHIC) — 944KB
- ex99-1_006.jpg (GRAPHIC) — 1173KB
- ex99-1_007.jpg (GRAPHIC) — 892KB
- ex99-1_008.jpg (GRAPHIC) — 763KB
- ex99-1_009.jpg (GRAPHIC) — 686KB
- ex99-1_010.jpg (GRAPHIC) — 932KB
- ex99-1_011.jpg (GRAPHIC) — 772KB
- ex99-1_012.jpg (GRAPHIC) — 1084KB
- ex99-1_013.jpg (GRAPHIC) — 1341KB
- ex99-1_014.jpg (GRAPHIC) — 930KB
- ex99-1_015.jpg (GRAPHIC) — 927KB
- ex99-1_016.jpg (GRAPHIC) — 923KB
- ex99-1_017.jpg (GRAPHIC) — 619KB
- ex99-1_018.jpg (GRAPHIC) — 569KB
- 0001641172-25-026758.txt ( ) — 22967KB
- biaf-20250905.xsd (EX-101.SCH) — 4KB
- biaf-20250905_def.xml (EX-101.DEF) — 26KB
- biaf-20250905_lab.xml (EX-101.LAB) — 36KB
- biaf-20250905_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 5, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-